[1] Gallardo G, Holtzman DM.Amyloid-β and Tau at the Crossroads of Alzheimer's Disease[J]. Adv Exp Med Biol, 2019, 1184: 187-203.
[2] Olsson B, Lautner R, Andreasson U, et al.CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis[J]. Lancet Neurol, 2016, 15(7): 673-684.
[3] Yamazaki Y, Kanekiyo T.Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease[J]. Int J Mol Sci, 2017, 18(9):1965.
[4] De-Paula VJ, Radanovic M, Diniz BS, et al.Alzheimer's disease[J]. Subcell Biochem, 2012, 65: 329-352.
[5] Chen GF, Xu TH, Yan Y, et al.Amyloid beta: structure, biology and structure-based therapeutic development[J]. Acta Pharmacol Sin, 2017, 38(9): 1205-1235.
[6] 张贺奡,庆宏. 阿尔茨海默症发病机制及治疗方法研究进展[J]. 科技导报,2017,35(10):52-63.
[7] 范春兰,唐民科. Aβ中枢及外周清除机制[J]. 生理科学进展,2016,47(2):139-143.
[8] Kurochkin IV, Guarnera E, Berezovsky IN.Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease[J]. Trends Pharmacol Sci, 2018, 39(1): 49-58.
[9] Nalivaeva NN, Turner AJ.Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy[J]. Br J Pharmacol, 2019, 176(18): 3447-3463.
[10] 张海静,赵春晖,张文生. β淀粉样蛋白跨血脑屏障转运机制研究进展[J]. 中国药理学通报,2016,32(10):1348-1352.
[11] 向阳. 阿尔茨海默病脑内Aβ的外周途径清除研究[D]. 第三军医大学,2016.
[12] 许兵,张俞,杜久林. 血脑屏障的研究进展[J].生理学报,2016,68(3):306-322.
[13] 周虎传,张玉波,刘磊. 血脑屏障结构的细胞学与分子学机制的研究现状[J]. 中国实用神经疾病杂志,2016,19(11): 98,108.
[14] 方招弟,徐武华. 阿尔茨海默病的血脑屏障研究进展[J]. 中国卒中杂志, 2019, 14(2):132-136.
[15] Montagne A, Zhao Z, Zlokovic BV.Alzheimer's disease: A matter of blood-brain barrier dysfunction[J]. J Exp Med, 2017, 214(11): 3151-3169.
[16] Reinhold AK, Rittner HL.Barrier function in the peripheral and central nervous system-a review[J]. Pflugers Arch, 2017, 469(1): 123-134.
[17] 梁跃霞,曹国琼,张文生. 阿尔茨海默症炎症反应及中药干预研究进展[J]. 中国药理学通报,2017,33(5):597-602.
[18] Cai Z, Liu N, Wang C, et al.Role of RAGE in Alzheimer's Disease[J]. Cell Mol Neurobiol, 2016, 36(4): 483-495.
[19] Fang F, Yu Q, Arancio O, et al.RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity[J]. Hum Mol Genet, 2018, 27(6): 1002-1014.
[20] Cai Z, Qiao PF, Wan CQ, et al.Role of Blood-Brain Barrier in Alzheimer's Disease[J]. J Alzheimers Dis, 2018, 63(4): 1223-1234.
[21] Kook SY, Hong HS, Moon M, et al.Aβ1-42-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²+-calcineurin signaling[J]. J Neurosci, 2012, 32(26): 8845-8854.
[22] Cuevas E, Rosas-Hernandez H, Burks SM, et al.Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro[J]. Metab Brain Dis, 2019, 34(5): 1365-1374.
[23] Hong Y, Shen C, Yin Q, et al.Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus[J]. Neurochem Res, 2016, 41(5): 1192-1199.
[24] 郑嵋戈,阮志刚,刘靖,等. β-淀粉样蛋白的代谢机制[J]. 神经解剖学杂志,2011,27(3):344-348.
[25] 刘斌. 补阳还五汤对APP/PS1双转基因小鼠神经血管单元RAGE/LRP1受体系统的调节机制[D]. 黑龙江中医药大学,2017.
[26] Shinohara M, Tachibana M, Kanekiyo T, et al.Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies[J]. J Lipid Res, 2017, 58(7): 1267-1281.
[27] Eggert S, Thomas C, Kins S, et al.Trafficking in Alzheimer's Disease: Modulation of APP Transport and Processing by the Transmembrane Proteins LRP1, SorLA, SorCS1c, Sortilin, and Calsyntenin[J]. Mol Neurobiol, 2018, 55(7): 5809-5829.
[28] Kim DE, Priefer R.Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer's Disease[J]. Brain Sci, 2020, 10(2): 93.
[29] 张云莎,郭茂娟,李虎虎,等. Aβ的外周清除与阿尔茨海默病[J]. 现代生物医学进展,2016,16(22):4398-4400,4338.
[30] Erdő F, Krajcsi P.Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier[J]. Front Aging Neurosci, 2019, 11: 196.
[31] 雷燕,张建华,张明,等. P-糖蛋白抑制剂研究进展[J]. 广州化工,2016,44(6):27-30.
[32] 任赵燕. 冰片对血脑屏障及P-糖蛋白影响的研究[D]. 山东中医药大学,2016.
[33] Huang L, Li B, Li X, et al.Significance and Mechanisms of P-glycoprotein in Central Nervous System Diseases[J]. Curr Drug Targets, 2019, 20(11): 1141-1155.
[34] Bruckmann S, Brenn A, Grube M, et al.Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease[J]. Curr Alzheimer Res, 2017, 14(6): 656-667.
[35] Osgood D, Miller MC, Messier AA, et al.Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier[J]. Neurobiol Aging, 2017, 57: 178-185.
[36] Hartz A, Zhong Y, Shen AN, et al.Preventing P-gp Ubiquitination Lowers Aβ Brain Levels in an Alzheimer's Disease Mouse Model[J]. Front Aging Neurosci, 2018, 10: 186.
[37] 田金洲,时晶. 阿尔茨海默病的中医诊疗共识[J]. 中国中西医结合杂志,2018,38(5):523-529.
[38] 臧彩霞,鲍秀琦,孙华,等. 中药复方治疗阿尔茨海默症的研究进展[J]. 中药药理与临床,2016,32(4):157-161.
[39] 张云莎,杨琳,庞赓,等. 银杏内酯和银杏黄酮干预β-淀粉样蛋白跨血脑屏障低氧模型转运的体外研究[J]. 广东医学, 2016,37(16):2389-2392.
[40] 郑尧杰,尤付玲,李巧,等. 远志皂苷调控RAGE和LRP1的抗Aβ诱导的氧化应激作用研究[J]. 广东药学院学报,2016, 32(2):201-204.
[41] 郭园园,郑琴,吴玲,等. 四君子汤调控Aβ跨血脑屏障转运相关蛋白的作用研究[J]. 中国中药杂志,2020,45(12):2924-2931.
[42] 王竟静,农汝楠,覃乐,等. 血脑屏障模型及中药对其通透性影响研究进展[J]. 中国实验方剂学杂志,2020,26(9): 225-234.
[43] He JT, Zhao X, Xu L, et al.Vascular Risk Factors and Alzheimer's Disease: Blood-Brain Barrier Disruption, Metabolic Syndromes, and Molecular Links[J]. J Alzheimers Dis, 2020, 73(1): 39-58.
[44] 陈庆华,张凤强,李立新,等. 阿尔茨海默病发病机制和诊断技术研究进展[J]. 中华老年心脑血管病杂志,2018,20(1):108-110. |
